Tirzepatide Cardiovascular Research: What Clinical Trials Show | TelosRX | telos rx
Person in athletic shoes running up outdoor stairs
← Back to blog
cardiovascular

Tirzepatide Cardiovascular Research: What Clinical Trials Show

By TelosRX Medical Team

Tirzepatide cardiovascular research from multiple clinical trials shows significant reductions in blood pressure, cholesterol, heart failure events, and major adverse cardiac events. Here's what the published evidence actually says — and what it means for your evaluation at TelosRX.

Most people asking about tirzepatide want to know: will it help me lose weight? Fair question. But a growing body of research points to something beyond the scale — consistent improvements in cardiovascular risk markers that cardiologists and endocrinologists are now taking seriously.

This review walks through what key trials actually found, where the evidence is strong, and where gaps remain. All claims trace to published sources cited below.

What Is Tirzepatide and Why Does It Affect the Heart?

Tirzepatide is a dual GLP-1 / GIP receptor agonist — meaning it activates two different metabolic hormone receptors simultaneously. GLP-1 receptors are expressed in the heart and blood vessels. GIP receptors appear on adipose tissue, the gut, and possibly cardiomyocytes. This dual mechanism is why tirzepatide may have cardiovascular effects that go beyond simple weight loss.

Compounded tirzepatide is not FDA-approved. The brand-name versions — Mounjaro (for type 2 diabetes) and Zepbound (for obesity management) — hold FDA approval. Any clinical application of compounded tirzepatide is subject to medical approval by a licensed provider.

Finding 1: SURPASS Trials — Blood Pressure and Lipid Reductions

The SURPASS program ran six major phase 3 randomized controlled trials in patients with type 2 diabetes. Across all arms, tirzepatide produced consistent reductions in:

  • Systolic blood pressure: up to 11 mmHg at 15 mg/week
  • LDL cholesterol: reductions of 6–12% across doses
  • Triglycerides: reductions of 18–37% across doses
  • HbA1c: average reductions of 2.0–2.6% — greater than any comparator in every trial

The SURPASS-2 trial compared tirzepatide head-to-head against semaglutide 1 mg. At 40 weeks, tirzepatide 15 mg reduced triglycerides by 24.8% vs 11.5% for semaglutide — a clinically meaningful gap in a key atherogenic marker. (Frías et al., NEJM, 2021.)

These aren't surrogate markers researchers invented. Blood pressure, LDL, and triglycerides are independent cardiovascular risk factors with decades of outcome data behind them. See our overview of tirzepatide vs. semaglutide for a full comparison of the two drugs' metabolic profiles.

Finding 2: Heart Failure Research — The 2024 NEJM Trial

A pivotal 2024 trial published in the New England Journal of Medicine examined tirzepatide specifically in patients with heart failure with preserved ejection fraction (HFpEF) — a condition where the heart muscle doesn't relax properly, particularly common in obesity. This is a tough population to treat.

Results at 104 weeks showed:

  • Cardiovascular death or worsening heart failure: 9.9% (tirzepatide) vs 15.3% (placebo) — hazard ratio 0.62, statistically significant
  • Worsening heart-failure events alone: 8.0% vs 14.2% — hazard ratio 0.54
  • Patient-reported symptom scores (KCCQ-CSS): improved by 19.5 points vs 12.7 in the placebo group

This was a pre-specified cardiovascular endpoint trial — not a secondary analysis. The reduction in worsening heart failure events is among the stronger signals seen with any metabolic therapy in this indication. That said, this research used brand-name tirzepatide under controlled trial conditions, not compounded versions. Individual results will vary.

Study Population Duration Key CV Finding Significance
SURPASS-2 (NEJM 2021) T2DM 40 weeks Triglycerides ↓24.8%, SBP ↓6.5 mmHg vs semaglutide p<0.001
SURPASS-4 (Lancet 2021) T2DM + high CV risk 52 weeks MACE HR 0.50 at 15 mg vs insulin glargine Pre-specified meta-analysis
HFpEF Trial (NEJM 2024) Obesity + HFpEF 104 weeks CV death or worsening HF HR 0.62 p=0.026
JACC Advances 2025 Cardiometabolic disease ~12 months MACE HR 0.60 vs GLP-1 monotherapy p=0.003
SCAI 2026 (post-PCI) T2DM after PCI 12 months Mortality RR 0.38 vs dulaglutide p<0.001

Finding 3: MACE Reduction in Real-World Data (JACC Advances, 2025)

A 2025 observational study published in JACC Advances compared tirzepatide against GLP-1 receptor monotherapy (semaglutide/liraglutide) in nearly 48,000 adults using propensity-score matching. At roughly 12 months of follow-up:

  • Primary composite (AMI + ischemic stroke + all-cause mortality): HR 0.60, p=0.003
  • Acute myocardial infarction alone: HR 0.59, p=0.016
  • Heart failure exacerbation: HR 0.61, p=0.040
  • New-onset atrial fibrillation: HR 0.23, p=0.004

This is real-world data — patients with the full complexity of clinical practice, not trial eligibility criteria. Observational studies have inherent limitations (confounding by indication, selection bias), but propensity-score matching helps level the field. The atrial fibrillation signal is worth watching in ongoing prospective trials.

If you're evaluating compounded GLP-1 options, our compounded tirzepatide access guide explains how the asynchronous TelosRX evaluation process works — subject to provider review and approval.

Finding 4: 2026 Post-PCI and Post-TAVR Data

Two studies presented at the SCAI 2026 Scientific Sessions expanded the evidence into interventional cardiology populations — patients who had already undergone invasive cardiac procedures.

Post-PCI data (1,281 patients): Among T2DM patients who received tirzepatide vs. dulaglutide at the time of percutaneous coronary intervention:

  • MACE rate ratio: 0.46 (p<0.001) at one month
  • All-cause mortality at one year: RR 0.38 (p<0.001)
  • Cardiac arrest: RR 0.32 (p<0.001)

Post-TAVR data: In patients with obesity undergoing transcatheter aortic valve replacement, those not receiving tirzepatide faced 44% more frequent MACE and 54% higher hospitalization for acute heart failure. Researchers emphasized that prospective randomized trials are needed to confirm these findings.

Both studies used the TriNetX real-world database. They are retrospective — causation cannot be established from these designs alone. But they add to a consistent directional signal across multiple settings and populations.

What This Research Means Clinically

Tirzepatide's cardiovascular effects appear to work through several pathways simultaneously: direct weight reduction (which lowers cardiac load), improved insulin sensitivity, anti-inflammatory effects, reduced arterial stiffness, and likely direct receptor-mediated effects in cardiac tissue. The PMC narrative review (2023) maps these mechanisms in detail.

What the research does NOT establish yet:

  • Whether compounded tirzepatide produces identical cardiovascular outcomes to the brand-name drug
  • Long-term outcomes beyond 2 years in primary prevention populations
  • Benefit in patients without obesity or diabetes

The ongoing SURPASS-CVOT trial (NCT04255433) is designed to provide a definitive answer on major cardiovascular events. Results are expected to further clarify the benefit profile.

For people managing excess weight alongside cardiovascular risk factors, this evidence is part of what a TelosRX provider reviews during your clinical evaluation and side-effect management discussion. See also: how to manage a GLP-1 weight loss plateau.

Frequently Asked Questions

Does tirzepatide reduce cardiovascular risk?

Multiple clinical trials and real-world studies show tirzepatide is associated with reductions in major adverse cardiovascular events (MACE), blood pressure, LDL cholesterol, and triglycerides. The 2025 JACC Advances study found a 40% relative risk reduction in MACE vs. GLP-1 monotherapy. These findings are from branded tirzepatide under clinical conditions; results with compounded versions may vary and are subject to provider evaluation.

What does research show about tirzepatide and heart failure?

A 2024 NEJM trial in heart failure with preserved ejection fraction (HFpEF) found tirzepatide reduced the risk of cardiovascular death or worsening heart failure events by 38% over 104 weeks (HR 0.62, p=0.026). HFpEF is one of the hardest heart conditions to treat, which makes this finding particularly notable. Studies suggest the benefit is driven by weight loss, improved cardiac mechanics, and reduced inflammation.

Is compounded tirzepatide as effective as brand Mounjaro or Zepbound for heart health?

Compounded tirzepatide is not FDA-approved, and head-to-head cardiovascular outcome data comparing compounded vs. branded tirzepatide does not exist. The cardiovascular trial evidence cited in this article used FDA-approved branded versions. Any discussion of compounded tirzepatide's potential benefit should involve a licensed provider's assessment of your individual risk profile.

Can tirzepatide lower blood pressure?

Yes — consistently across all SURPASS trials. The 15 mg dose reduced systolic blood pressure by up to 11 mmHg. In the SURMOUNT-1 ambulatory sub-study, tirzepatide reduced mean 24-hour systolic BP significantly vs. placebo. A modest heart rate increase was also observed, which is worth monitoring for some patients.

What is the SURPASS-CVOT trial?

SURPASS-CVOT (NCT04255433) is an ongoing randomized trial comparing tirzepatide to dulaglutide on major cardiovascular events in 13,299 patients with T2DM and established or high-risk cardiovascular disease. It is designed to provide the gold-standard answer on whether tirzepatide's metabolic improvements translate to fewer heart attacks and strokes over time.

Is tirzepatide safe for people with existing heart disease?

Data from the SURPASS trials and multiple observational studies suggest tirzepatide does not increase cardiovascular risk — and may reduce it — in people with established cardiovascular disease or high risk. A pre-specified SURPASS meta-analysis found no increase in MACE. However, every individual's situation differs. This requires evaluation by a licensed provider before starting any regimen.

TelosRX is LegitScript-certified. Compounded medications are not FDA-approved and are prepared under federal compounding regulations. Approval is subject to evaluation by a licensed provider; approval is not guaranteed. Individual results vary. TelosRX operates as an online-first, asynchronous telehealth service.

Start your private evaluation at TelosRX.

Related research

Compounded medications are compounded, not FDA-approved. Prescriptions are never automatic or guaranteed. TelosRX operates under LegitScript-certified telehealth standards as an online-first, asynchronous telehealth service.

Read more from TelosRX